Featured Research

from universities, journals, and other organizations

Vaccines From The Bioreactor: Bioprocess Increases Vaccine Yield

Date:
June 24, 2009
Source:
Empa
Summary:
Vaccinations are the most effective weapons in the fight against infectious diseases. However, developing novel vaccines alone is not sufficient to win the battle and the development and manufacture of economically priced vaccines in sufficient quantities represent real research challenges. Swiss researchers have developed a new bioprocess which increases the vaccine yield by a factor of fifty compared to conventional techniques.

Empa researchers have successfully scaled-up a new method of producing vaccines to enable the use of a bioreactor.
Credit: Image courtesy of Empa

Empa researchers have managed to adapt a process for manufacturing certain vaccines – in particular that against Haemophilus influenae bacteria – for use in bioreactors, with the result that the yield is enhanced enormously. Haemophilus influenzae not only causes serious infection in the nose and throat, but can result in potentially fatal meningitis. The Swiss Federal Vaccination Commission therefore strongly recommends that children be vaccinated against this organism.

So-called conjugate vaccines have proven to be especially safe and effective in this respect. In this technique, antigens in the form of sugar chains (oligosaccharides) are chemically linked to carrier proteins in a complex process known as glycosylation.

Designer bacteria instead of chemical processes

A more elegant way, however, is to allow this task to be performed by specially designed, non-toxic Escherichia coli bacteria, which are normally present in the human gut. For this purpose GlycoVaxyn has developed an enzyme-based in vivo method. The Escherichia coli bacteria were genetically modified, so that they glycosylate certain proteins – in order words, they generate vaccine material. Unfortunately, however, the yield in the GlycoVaxyn process was too low. The vaccine manufacturer needed the help of specialists to upscale their process so it could be used in bioreactors. Their search came to an end in Empa’s Biomaterials laboratory, where both the necessary know-how and the bioreactors were at hand.

From cell culture to bioreactor

“This is a classic biotechnology 'scale-up-problem'. It is not simply a question of multiplying everything by a hundred,” explains Empa expert Julian Ihssen. ”On a large scale everything becomes more difficult. At higher cell densities many factors change.” For example, Escherichia coli bacteria begin to produce acetic acid. The oxygen supply is also no longer optimal. This makes the results very difficult to predict.

The Empa researchers discovered that the production of the glycoconjugate, i.e. the vaccine itself, was influenced by both the type of culture medium used as well as the way the process steps were controlled. Several different process sequences were tried out, with the best turning out to be a «fed-batch» strategy involving the periodic addition of glycerol as the main nutrient.

A significantly higher vaccine yield

The novel bioprocess resulted in a forty times increase in the biomass concentration – that is, the bacterial cell density – compared to the previously employed shaken flask technique. At the same time each individual bacteria produced on average somewhat more vaccine than before, so that all told the yield in purified conjugated vaccine rose from 0.6 to over 30 milligrams per liter of culture medium, an increase of about a factor fifty. “The results using a three liter bioreactor were very promising. Now we are hoping to be able to scale up the principle even more to the industry standard level,” says GlycoVaxyn co-founder Michael Wacker.

The same process can very likely also be used to manufacture other conjugated vaccines too, for instance against certain diarrhea producing organisms, or salmonella. This would above all offer a glimmer of hope to developing countries, where often vaccination campaigns fail because of the high price of vaccines.


Story Source:

The above story is based on materials provided by Empa. Note: Materials may be edited for content and length.


Cite This Page:

Empa. "Vaccines From The Bioreactor: Bioprocess Increases Vaccine Yield." ScienceDaily. ScienceDaily, 24 June 2009. <www.sciencedaily.com/releases/2009/06/090612122455.htm>.
Empa. (2009, June 24). Vaccines From The Bioreactor: Bioprocess Increases Vaccine Yield. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2009/06/090612122455.htm
Empa. "Vaccines From The Bioreactor: Bioprocess Increases Vaccine Yield." ScienceDaily. www.sciencedaily.com/releases/2009/06/090612122455.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WHO Calls for Ban on E-Cigarette Sales to Minors

WHO Calls for Ban on E-Cigarette Sales to Minors

AFP (Aug. 26, 2014) — The World Health Organization called Tuesday on governments should ban the sale of e-cigarettes to minors, warning that they pose a "serious threat" to foetuses and young people. Duration: 01:44 Video provided by AFP
Powered by NewsLook.com
Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Newsy (Aug. 26, 2014) — A study published in the journal "Neurology" interviewed more than 19,000 people and found 15 percent suffer from being "sleep drunk." Video provided by Newsy
Powered by NewsLook.com
Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Newsy (Aug. 26, 2014) — A new study found fewer deaths from prescription drug overdoses in states that have legalized medical marijuana. But experts disagree on the results. Video provided by Newsy
Powered by NewsLook.com
Official: British Ebola Sufferer Receiving Experimental Drug

Official: British Ebola Sufferer Receiving Experimental Drug

AFP (Aug. 26, 2014) — A British nurse infected with Ebola while working in Sierra Leone is being given the same experimental drug used on two US missionaries who have recovered for the disease, doctors in London say. Duration: 00:44 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:  

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile iPhone Android Web
    Follow Facebook Twitter Google+
    Subscribe RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins